Immuneering Corp
IMRX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001790340
No open-market purchases or sales by Immuneering Corp insiders were filed in the last 90 days; 111 institutions reported holding it in 13F filings for Q2 2026, worth $171.6M in total; no superinvestor holds it.
Q4 2023 vs. Q3 2023
How the institutions holding Immuneering Corp changed between Q3 2023 and Q4 2023.
All holders in Q4 2023All holders in Q3 2023
| Measure | Q3 2023 | Q4 2023 | Change |
|---|---|---|---|
| Holders | 52 | 52 | 0 |
| Shares | 16.9M | 16.1M | −810.1K (−4.8%) |
| Value | $130.1M | $118.6M | −$11.5M (−8.9%) |
New holders (4)
Institutions that held Immuneering Corp at the end of Q4 2023 but not at the end of Q3 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Oracle Alpha Inc. | 11,794 | $86.7K | 0.11% |
| Millennium Management LLC | 11,438 | $84.1K | 0.00% |
| Virtu Financial LLC | 11,409 | $84.0K | 0.01% |
| Susquehanna International Group, LLP | 10,603 | $77.9K | 0.00% |
Sold out (4)
Institutions that held Immuneering Corp at the end of Q3 2023 and filed for Q4 2023 without it.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| Invesco Ltd. | 10,249 | $78.7K |
| China Universal Asset Management Co., Ltd. | 749 | $5.75K |
| Daiwa Securities Group Inc. | 76 | $1.00K |
| Federated Hermes, Inc. | 75 | $576 |